Invivyd grants stock options to 17 new employees as hiring incentive under Nasdaq rules.

Invivyd, a biopharmaceutical company, granted stock options to 17 newly hired non-executive employees as a material inducement for joining the company. The options cover 731,000 shares at an exercise price of $1.52, the closing price on the grant date, and vest over four years with a 10-year term. This move aligns with Nasdaq Listing Rule 5635(c)(4) and supports Invivyd's growth by attracting talent. Invivyd focuses on developing antibody treatments for viral diseases, including a monoclonal antibody authorized for emergency use by the FDA in 2024.